Lamotrigine, an antiepileptic drug, inhibits 5-HT3 receptor currents in NCB-20 neuroblastoma cells

Ki Jung Kim; Seung Hyun Jeun; Ki-Wug Sung

doi:10.4196/kjpp.2017.21.2.169

Journal List > Korean J Physiol Pharmacol > v.21(2) > 1026157

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Kim, Jeun, and Sung: Lamotrigine, an antiepileptic drug, inhibits 5-HT3 receptor currents in NCB-20 neuroblastoma cells

Original Article

The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology 2017; 21(2): 169-177.

Published online: 21 February 2017

DOI: https://doi.org/10.4196/kjpp.2017.21.2.169

Lamotrigine, an antiepileptic drug, inhibits 5-HT₃ receptor currents in NCB-20 neuroblastoma cells

Ki Jung Kim¹, Seung Hyun Jeun², Ki-Wug Sung²

¹Department of Physiology, Augusta University, Augusta, GA 30912, USA.

²Department of Pharmacology, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.

Correspondence Ki-Wug Sung. sungkw@catholic.ac.kr

Received 8 September 2016 Revised 29 November 2016 Accepted 18 December 2016

(open-access, http://creativecommons.org/licenses/by-nc/4.0):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Lamotrigine is an antiepileptic drug widely used to treat epileptic seizures. Using whole-cell voltage clamp recordings in combination with a fast drug application approach, we investigated the effects of lamotrigine on 5-hydroxytryptamine (5-HT)₃ receptors in NCB-20 neuroblastoma cells. Co-application of lamotrigine (1~300 µM) resulted in a concentration-dependent reduction in peak amplitude of currents induced by 3 µM of 5-HT for an IC₅₀ value of 28.2±3.6 µM with a Hill coefficient of 1.2±0.1. These peak amplitude decreases were accompanied by the rise slope reduction. In addition, 5-HT₃-mediated currents evoked by 1 mM dopamine, a partial 5-HT₃ receptor agonist, were inhibited by lamotrigine co-application. The EC₅₀ of 5-HT for 5-HT₃ receptor currents were shifted to the right by co-application of lamotrigine without a significant change of maximal effect. Currents activated by 5-HT and lamotrigine co-application in the presence of 1 min pretreatment of lamotrigine were similar to those activated by 5-HT and lamotrigine co-application alone. Moreover, subsequent application of lamotrigine in the presence of 5-HT and 5-hydroxyindole, known to attenuate 5-HT₃ receptor desensitization, inhibited 5-HT₃ receptor currents in a concentration-dependent manner. The deactivation of 5-HT₃ receptor was delayed by washing with an external solution containing lamotrigine. Lamotrigine accelerated the desensitization process of 5-HT₃ receptors. There was no voltage-dependency in the inhibitory effects of lamotrigine on the 5-HT₃ receptor currents. These results indicate that lamotrigine inhibits 5-HT₃-activated currents in a competitive manner by binding to the open state of the channels and blocking channel activation or accelerating receptor desensitization.

Keywords: 5-HT₃ receptor, Antiepileptic drug, Lamotrigine, NCB-20 cell, Open state block

INTRODUCTION

5-Hydroxytryptamine (5-HT)₃ receptors are the only ligand-gated ion channels (LGIC) among the subfamilies of 5-HT receptors. Based on structural and functional properties, 5-HT₃ receptors are members of the Cys-loop family of LGIC, which includes glycine, GABAA and nicotinic acetylcholine (nACh) receptors [1 2 3 4]. These receptors are widely distributed in the central and peripheral nervous systems [5 6 7]. Given their expression at both pre- and post-synaptic terminals, their activation modulates the release of various neurotransmitters such as dopamine, cholecystokinin, GABA, substance P and acetylcholine. Moreover, antagonism of 5-HT₃ receptors results in antiemetic [8], anxiolytic [9], and antipsychotic effects [10] suggesting an important role of this receptor in neuronal function. 5-HT₃ receptors are remarkably sensitive to a number of pharmacological agents, thus constituting important therapeutic target for the treatment of neuronal disorders such as schizophrenia, depression and anxiety [3 7]. Furthermore, it has been reported that 5-HT₃ receptor agonist, 1-(m-chlorophenyl)-biguanide (m-CPBG), increases the duration of fully kindled seizures and facilitates the developmental seizure process in a kindling model of epilepsy [11]. This result suggests that 5-HT₃ receptor activation leads to an increase in neuronal excitation [12 13].

Lamotrigine [3,5-diamino-6-(2,3-dichlorophenyl)-1,2,3-trazine] is an antiepileptic drug effective in treating most seizure types [14]. Although the cellular and molecular mechanisms of lamotrigine are still unknown, it has been proposed that the antiepileptic effects can be ascribed to the inhibition of voltage-gated Na⁺ channels, resulting in blockade of the release of excitatory amino acid transmitters [15]. It has been also reported that lamotrigine acts as an open channel blocker for the nACh receptor [16 17], and alters 5-HT release in a rat brain [18 19]. Moreover, lamotrigine modulates 5-HT uptake in rats [20]. Altogether these results suggest lamotrigine as a potential agent in the treatment of neuropsychiatric disorders such as schizophrenia, bipolar disorder, and anxiety disorders [21].

A study using a binding assay method reported that lamotrigine weakly binds to 5-HT₃ receptors [22]. However, no studies have addressed its role on 5-HT₃ receptors using electrophysiological techniques to better assess the functional outcomes of its binding to the receptor. Thus, using the whole-cell patch clamp in combination with a fast drug application approach, we tested the effects of lamotrigine on 5-HT₃ receptor function. Based on our results we suggest an additional pharmacological mechanism with therapeutic potential for neuropsychiatric disorders associated with 5-HT₃ receptor dysfunction.

METHODS

Cell culture

NCB-20 neuroblastoma cells (kindly provided by Dr. Lovinger, National Institute on Alcohol Abuse and Alcoholism, USA) were maintained under conditions previously described conditions [23]. Frozen cell stocks were maintained in liquid nitrogen, and thawed as needed. Cells were maintained in a medium containing 90% Dulbecco's modified Eagle's medium, 10% fetal bovine serum, and 1% hypoxanthine aminopterin thymidine supplement, and were cultured in an incubator containing 5% CO₂ at 37℃. Cells were seeded on 35 mm culture dishes at least 24 h prior to electrophysiological experiments.

Electrophysiology

For whole-cell patch-clamp recordings, NCB-20 cells were plated on cover glasses (12 mm diameter; Fisher Scientific, Pittsburgh, PA, USA) and transferred to the recording chamber (RC-13, Warner Instruments, Hamden, CT, USA) mounted on the stage of an inverted microscope (IX70, Olympus, Tokyo, Japan) at room temperature (21~24℃), as previously described [23]. Cells were continuously perfused with an extracellular solution containing (in mM) 150 NaCl, 2.5 KCl, 2.5 CaCl₂, 10 N-(2-hydroxyethyl)piperazine-N′-2-ethansulfonic acid (HEPES), and 10 D-glucose (pH adjusted to 7.4 with NaOH and osmolality adjusted to 340 mOsm/kg with sucrose) at a rate of 2~3 ml/min through the theta glass micropipette (see below in Drug preparation and application) . Patch pipettes were pulled from borosilicate glass capillaries (1B150-4, World Precision Instruments, Sarasota, FL, USA) using a programmable horizontal micropipette puller (P-97, Sutter Instrument, Novato, CA, USA). Pipette tips had resistances of 2.0~3.0 MΩ when filled with an internal solution containing (in mM) 140 CsCl, 2 MgCl₂, 5 ethylene glycol bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA), 10 HEPES, (pH adjusted to 7.2 with CsOH, osmolality adjusted to 310 mOsm/kg with sucrose). Whole-cell currents were recorded using an Axopatch 200B amplifier and pClamp 9.2 software (Molecular Devices, Sunnyvale, CA, USA). All experiments were carried out at a holding potential of –50 mV unless otherwise stated. The current signals were filtered at 2 kHz, digitized at 10 kHz, and saved on a PC using DigiData 1322 and pClamp 9.2 software (Molecular Devices). The liquid junction potentials between the pipette and bath solutions were 3~5 mV, and were zeroed before a gigaohm seal was formed. Capacitive currents were compensated with analog compensation, but leak subtraction was not used in this study.

After achieving a whole-cell configuration, a variable amount of current run-down was typically observed for several minutes. To minimize run-down condition, we waited at least 10 min after getting whole-cell configuration, and drug applications were carried out at 2 min intervals. At the end of the experiments, 5-HT-induced currents that decreased more than 20% in comparison with the first current were excluded from the data analysis.

Drug preparation and application

A fast drug application technique was used to induce the 5-HT₃ receptor currents and to evaluate the drug effects as previously described [23]. After establishing a whole-cell configuration, cells were lifted up and positioned in front of one side of theta glass micropipette, which was pulled from the theta glass tubing (Clark Borosilicate Theta, Warner Instruments; 2 mm outer diameter, 1.4 mm inner diameter, 0.2 mm septum thickness) to an outer diameter of ~300 µm, and continuously perfused with an extracellular solution. The extracellular solution, which contained agonists with or without drug, flowed through a different side of the theta glass micropipette. Solutions were rapidly switched around the cell by the linear movement of theta glass micropipette mounted on a piezoelectric translator (P-601 PiezoMove Z Acturator, Physik Instrumente, Karlsruhe, Germany), which displaced the theta glass micropipette laterally so that the cell could be exposed for a defined period of time to the drug-containing solution, and then rapidly returned to the drug-free extracellular solution. The piezoelectric translator was controlled by a Piezo Servo Controller (E-625, Physik Instrumente) and triggered by pClamp 9.2 software (Molecular Devices). The rate of solution exchange was usually 24.4±5.3 msec (n=11) in the open pipette tip configuration [24]. Solution flow was driven by gravity from reservoirs placed above the preparation, and the application of solutions was controlled by a perfusion valve control system (VC-8, Warner Instruments, Hamden, CT, USA).

The agonist and other drugs were diluted in the extracellular solution from stock solutions in distilled water. Lamotrigine was dissolved in dimethyl sulfoxide (DMSO, 30 mM stock) and further diluted in the extracellular solution with or without the agonist. Lamotrigine was purchased from Santa Cruz Biotechnology (Dallas, Texas, USA). All other chemicals were purchased from Sigma Chemicals (St. Louis, MO, USA). Cell culture reagents were obtained from Gibco BRL (Rockville, MD, USA). Solutions were freshly prepared prior to each experiment.

Data analysis and statistics

Peak amplitudes of currents were measured using Clampfit 9.2 software (Molecular Devices), by determining the differences in currents before and during agonist application. The rise slopes of current were also analyzed to evaluate 5-HT₃ receptor activation using the built-in statistical tools in Clampfit 9.2 software. Since peak amplitudes of the 5-HT₃ receptor currents induced by agonist application varied among cells, data were normalized to the maximal values in each cell. Receptor desensitization was measured as the decay in the 5-HT₃ receptor currents in the continuous presence of the agonist (10 sec). Receptor deactivation was measured as the current decay in response after brief application of the agonist for 10 msec. Both current decays by desensitization and deactivation were fitted to a double exponential function, then analyzed and compared the time constants for fast and slow component of current decays.

Concentration–response data were fitted to a sigmoid curve, as calculated by the four-parameter logistic equation using Prism 4.0 software (GraphPad Software, San Diego, CA, USA). For the EC₅₀ of 5-HT:

Y=bottom+(top-bottom)/(1+10^{((LogEC₅₀–X) Hillslope)}),

where the bottom is the minimal response, top is the maximal response by 5-HT, X is the logarithm of concentrations of tested agonist and EC₅₀ is the concentration of 5-HT that gives a response half way between bottom and top. For the IC₅₀ of lamotrigine:

Y=bottom+(top-bottom)/(1+10^{((LogIC₅₀–X) Hillslope)}),

where the bottom is the maximally inhibited response by lamotrigine, top is the maximal response by 5-HT alone, X is the logarithm of concentrations of lamotrigine and IC₅₀ is the concentration of lamotrigine resulting in a response half way between bottom and top.

The averaged values were expressed as mean±S.E.M. Statistical significance was determined by the Student's t-test. p<0.05 was considered to be statistically significance.

RESULTS

Inhibitory effects of lamotrigine on 5-HT₃ receptor activation

To determine the direct effects of lamotrigine on 5-HT₃ receptor currents, we studied the concentration-dependent responses of lamotrigine (1~300 µM) on the currents activated by 3 µM of 5-HT, near EC₅₀ of 5-HT₃ receptor currents in our previous report [23]. Application of lamotrigine (300 µM) alone did not induce any current (data not shown). Co-application of lamotrigine reduced the peak amplitudes of 3 mM 5-HT-induced currents in a concentration-dependent manner (Fig. 1A). The IC₅₀ value of lamotrigine for the peak amplitude reduction was 28.2±3.6 µM with a Hill coefficient of 1.2±0.1 (Fig. 1C, n=8). In addition to reducing the peak amplitude, lamotrigine also decreased the rise slope of 5-HT₃ receptor currents, an indicator of activation of the 5-HT₃ receptor [25], induced by 3 µM of 5-HT. The IC₅₀ value for the rise slope decreases by lamotrigine was 21.7±4.9 µM with a Hill coefficient of 1.4±0.2 (Fig. 1D, n=8).

To further investigate the effects of lamotrigine on 5-HT₃ receptor activation, we used dopamine (DA), a partial 5-HT₃ receptor agonist [26]. Currents activated by 1 mM of DA were characterized by a slow rise time, smaller peak amplitude (compared to that of a full agonist, i.e., 5-HT) and, either no decay or a small slow decay during DA application for 5 sec (Fig. 1B). It has been also reported that DA-induced currents in NCB-20 cells were completely blocked by zacopride, a potential and highly selective 5-HT₃ receptor antagonist [26]. These results suggest that DA directly activates the 5-HT₃ receptors without strong desensitization. Therefore, it is possible to clarify further effects of lamotrigine on the activation or the open process of 5-HT₃ receptors [26]. We then studied the effect of lamotrigine (1~300 µM) on 1 mM DA-induced currents (Fig. 1B). Co-application of lamotrigine with DA reduced the peak amplitude in a concentration-dependent manner. The IC₅₀ value of the peak amplitude was 18.2±6.7 µM with a Hill coefficient of 1.3±0.6 (Fig. 1E, n=6). The IC₅₀ values of lamotrigine on the inhibition of peak amplitude were similar between the 5-HT₃ receptor currents activated by a full agonist, 5-HT and a partial agonist, DA. These results suggest that the inhibitory action of lamotrigine on 5-HT₃ receptors resulted from the blockade of the channel activation process.

Fig. 2A shows the representative 5-HT₃ receptor currents evoked by 1, 3, 10, 30 µM of 5-HT with or without lamotrigine co-application (30 µM, near IC₅₀ based on other experiments mentioned in this study) to study whether lamotrigine inhibits the 5-HT₃ receptor competitive manner. Co-application of lamotrigine attenuated the currents activated by 0.1~30 µM of 5-HT (Fig. 2B). EC₅₀ value of peak currents induced by application of 5-HT alone was 3.4±0.1 µM with Hill coefficient of 2.5±0.3 (n=9). EC₅₀ value of peak currents induced by co-application of 5-HT and 30 µM of lamotrigine was 4.2±0.3 µM with Hill coefficient of 2.3±0.1 (n=9). Co-application of 30 µM of lamotrigine increased the EC₅₀ (p<0.05, unpaired t-test) however, the Hill coefficient change was not statistically significant (p=0.5698). The maximum of peak currents, reached at 30 µM of 5-HT, were not significantly different between those with and without 30 µM of lamotrigine (96.1±4.0% and 104.1±1.9% of 10 µM 5-HT response, respectively; p=0.0843, unpaired t-test). These results suggest that lamotrigine inhibits 5-HT₃ receptor activation in a competitive manner.

In order to determine whether the lamotrigine also affects the closed state of the 5-HT₃ receptor, cells were pretreated with 30 µM lamotrigine for 1 min prior to the co-application of 3 µM 5-HT with lamotrigine, and compared to 3 µM 5-HT and 30 µM lamotrigine co-applications without pretreatment of lamotrigine (Fig. 3A). Following a 1 min pretreatment, no differences were observed in the inhibition of peak amplitudes by the co-application of 5-HT and lamotrigine after 1 min pretreatment (50.4±1.2% of 5-HT only) when compared to the co-application without pretreatment of lamotrigine (50.6±1.8%) (Fig. 3B, n=8, p=0.8586, paired t-test). These results indicate that lamotrigine is unlikely to bind to the closed state of the receptor but readily binds to the open or active state.

To address, in detail, the effects of lamotrigine on the 5-HT₃ receptor open state, we next applied lamotrigine (1~300 µM) on 5-HT (10 µM) and 5-hydroxyindole (5-HI, 1 mM)-induced currents (Fig. 4). Our previous report showed that 1 mM 5-HI blocked the desensitization of 10 µM 5-HT-induced currents without changes in peak amplitude [24], which remained 5-HT₃ receptor to open or activated states. The currents activated by 10 µM 5-HT with 1 mM 5-HI were decreased following subsequent application of lamotrigine in a concentration-dependent manner. A concentration of 300 µM lamotrigine was sufficient to cause a complete blockade of the currents (Fig. 4A). The IC₅₀ value of lamotrigine for the inhibition of open state of the 5-HT₃ receptor was 36.6±2.2 µM with a Hill coefficient of 0.5±0.1 (Fig. 4B, n=9).

Effects of lamotrigine on 5-HT₃ receptor deactivation and desensitization

To examine if lamotrigine could alter 5-HT₃ receptor deactivation, exposure to the external solution in the presence or absence of 30 µM lamotrigine, followed immediately after a brief application of 5-HT for 10 msec (Fig. 5A). A high 5-HT concentration (10 µM) was used to induce more profound channel deactivation following activation. The decay of 5-HT₃ receptor currents induced by application of 10 µM 5-HT for 10 msec were fitted to a double exponential function and analyzed the fast and slow component of time constants for current decay. As shown in Fig. 5B, the presence of lamotrigine (30 µM) after 10 msec application of 5-HT slowed the current decay. The slow decay time constant was increased from 1640.6±74.3 to 1961.9±100.9 msec (n=8, p<0.05, paired t-test). However, the time constant for fast current decay was not changed by lamotrigine (322.2±36.7 msec for 5-HT alone and 312.1±47.3 msec for lamotrigine washing, n=8, p=0.6343, paired t-test). These results suggest that lamotrigine attenuates the deactivation of 5-HT₃ receptors after channel opening.

The effect of lamotrigine on the 5-HT₃ receptor desensitization was also studied using a long application of 5-HT to induce the receptor desensitization with or with lamotrigine, then analyzed current decay time constants. Fig. 5C shows the superimposed current traces induced by 10 µM of 5-HT (10 sec) with or without 30 µM of lamotrigine. The current decay during application of 5-HT was fitted to a double exponential function, and accelerated by co-application of lamotrigine. As shown in Fig. 5D, the time constant for fast current decays were not significantly changed by lamotrigine (455.2±28.2 msec for 5-HT alone and 482.1±40.6 msec for lamotrigine co-application, n=8, p=0.415, paired t-test), however the time constant for the slow component of current decays were decreased from 4640.0±632.8 to 3732.0±454.8 msec (n=8, p<0.01, paired t-test). These results suggest that lamotrigine accelerates the 5-HT₃ receptor desensitization after receptor activation.

Voltage-independence of lamotrigine on 5-HT₃ receptor inhibition

To evaluate the voltage-dependence of lamotrigine-induced inhibitory effects, 5-HT₃ receptor currents were recorded in the presence or absence of lamotrigine at different holding potentials (–50~+30 mV). Lamotrigine decreased 5-HT-induced currents over the entire voltage range tested (Fig. 6A). Fig. 6B shows a plot of 5-HT₃ receptor currents, induced by 3 µM of 5-HT and normalized to the currents at –50 mV of holding potential, against tested holding potentials in the presence or absence of lamotrigine (30 µM). Current-voltage relationships for peak amplitudes were almost linear, and calculated reversal potentials by linear regression were 3.4±0.5 mV and 3.5±0.7 mV in the absence and presence of lamotrigine, respectively. The reversal potential of 5-HT-induced currents was not changed by the co-application of lamotrigine (n=7, p=0.8076, paired t-test). The fractional blockade was calculated at the different holding potentials, and inhibitory effects of lamotrigine over all tested membrane potential ranges were similar in the presence of lamotrigine (Fig. 6C). These results indicate that the inhibitory actions of lamotrigine did not depend on voltage.

DISCUSSION

In the present study, we investigated the inhibitory actions of lamotrigine, an antiepileptic drug, on 5-HT₃ receptors naturally expressed in NCB-20 neuroblastoma cells. Our results suggest that lamotrigine inhibits 5-HT₃ receptor function predominantly by blocking channel opening, as substantiated by a lamotrigine-induced lowering of the peak amplitude accompanied with the reduction in the rise slope of currents, an indicator of activation of 5-HT₃ receptor [25], in concentration-dependent manner. Similar effects were obtained in DA experiments, under conditions were the channels are more likely to be in their open states without profound desensitization [26]. Thus, we suggest lamotrigine-induced inhibition of 5-HT₃ receptor function occurs during the receptor activation phase, i.e., channel open. This observation is supported by our finding that the pretreatment of lamotrigine for 1 min did not exert a significant effect on the 5-HT₃ receptor currents induced by co-application of 5-HT and lamotrigine, which suggesting the possibility of lamotrigine binding to closed state of 5-HT₃ receptors, and thereby block subsequent opening could be excluded. To further investigate the interaction of lamotrigine with the 5-HT₃ receptor during the open state of the receptor, experiments were conducted in the presence of 5-HI. In a previous report we showed that 1 mM 5-HI efficiently slowed 5-HT₃ receptor desensitization generated by 10 µM 5-HT without any effect on peak amplitudes [24]. Application of lamotrigine in the presence of 5-HT and 5-HI inhibited 5-HT₃ receptor currents in a concentration-dependent manner. These results also suggest that lamotrigine preferentially works in the open states of 5-HT₃ receptor and then inhibits the currents. In a series of these experiments, the calculated IC₅₀ values of lamotrigine on 5-HT₃ receptor currents showed little variance in a range of 20~40 µM. These results suggest that lamotrigine exerts 5-HT₃ receptor blocking through an open channel blocker.

Lamotrigine was also observed to alter the deactivation and desensitization properties of 5-HT₃ receptor channels, i.e. the slow time constants for current decays by the 5-HT₃ receptor deactivation were attenuated and the slow time constants for current decays by the 5-HT₃ receptor desensitization were accelerated by lamotrigine. As with many ligand-gated ion channels, channel deactivation and desensitization are correlated with the opening of the ion channels–for example, if more channels are activated, they will be more strongly deactivated and desensitized. In other words, if the degree of channel activation is increased, the rate of deactivation and desensitization is accelerated in an agonist concentration-dependent manner [25 27]. Therefore, the attenuation of 5-HT₃ receptor deactivation and the acceleration of receptor desensitization by lamotrigine in our experiment could be explained by secondary changes following inhibition of channel opening. However, a direct effect of lamotrigine on the deactivation and desensitization steps of the 5-HT₃ receptor could not be ruled out, because it has been reported that some drugs modulate 5-HT₃ receptor function directly acting on the receptor deactivation or desensitization process [28 29]. Thus, further studies elucidating the effect of lamotrigine on receptor deactivation and desensitization are needed.

In our study, lamotrigine caused an inhibition in peak amplitudes in a voltage-independent manner. The voltage-dependency of a drug effect is considered as evidence for a mechanism of open channel blocking in the voltage-gated ion channels as well as the ligand-gated ion channels, including 5-HT₃ receptors. For example, diltiazem acted as an open channel blocker on 5-HT₃ receptors and caused a voltage dependency [30]. However, lamotrigine is a basic drug with pKa5.7 [31] and predominates in its uncharged form at physiological pH. Therefore, it should be considered that if the major mechanism of action of lamotrigine on 5-HT₃ receptors is thought to involve the uncharged form of the drug, lamotrigine should block the currents in a voltage independent manner, even though it works as an open channel blocker on the 5-HT₃ receptors. These results suggest that lamotrigine could bind to the 5-HT₃ receptor voltage independently during activation and inhibits ion channel opening. This interpretation should be tested further, because our findings that the peak amplitude decreases accompanied with rise slope reduction (Fig. 1), no significant effects of 1 min pretreatment of lamotrigine (Fig. 3), and inhibition of open states of 5-HT₃ receptor by lamotrigine (Fig. 4), are all suggesting the open channel blocking mechanism of lamotrigine action. It has been reported that fluoxetine inhibited the 5-HT₃ receptor function with open channel blocking mechanism, but it showed voltage independency in its inhibition [32].Therefore, lamotrigine could act as an open channel blocker with voltage-independency.

5-HT₃ receptors modulate the release of various neurotransmitters such as dopamine, GABA and glutamate in the central nervous system [33 34 35], and are implicated in complex neuronal functions [1 8 36]. Reports for the antagonist of 5-HT₃ receptors indicate these receptors play important roles in neuropsychotropic actions such as schizophrenia [37 38]. In addition, lamotrigine blocks voltage-gated Na⁺ channel, which is believed to mediate its antiepileptic activity [39], resulting in blockade of the release of excitatory neurotransmitters [40]. Furthermore, other reports suggest that lamotrigine has a potential role in neuropsychiatric disorders [22 41]. Taken together with these reports, our results suggest that the 5-HT₃ receptor blocking by lamotrigine could be a potential mechanism of action in the clinical use of this drug to treat psychiatric and neurologic disorders.

In summary, we showed that lamotrigine inhibited 5-HT₃ receptor activation and 5-HT₃ receptor-induced currents. Lamotrigine decreased the amplitudes of 5-HT₃ receptor-mediated currents during the activation phase of the channel with changes in channel deactivation and desensitization properties. Therefore, lamotrigine blocks 5-HT₃ receptor-mediated currents by weakly binding to the open state of the receptors. Taken together, these results suggest that lamotrigine might contribute as a therapeutic agent for psychiatric and neurologic disorders, acting on the 5-HT₃ receptors.

ACKNOWLEDGEMENTS

We thank Dr. Lovinger (NIAAA, USA) for providing us with NCB-20 cells, and Prof. Hahn (The Catholic University of Korea) and Dr. Filosa (Augusta University, USA) for helpful comments on the preparation of this manuscript. This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and future Planning (NRF-2014R1A1A2056820).

Notes

Author contributions: Conception and design of study: K.J.K., K.W.S. Conducted experiments, acquisition of data, analysis and interpretation of data: K.J.K., S.H.J. Drafting the manuscript: K.J.K. Revising the manuscript: K.W.S.

CONFLICTS OF INTEREST: The authors declare no conflicts of interest.

References

1. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999; 38:1083–1152. PMID: 10462127.

2. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav. 2002; 71:533–554. PMID: 11888546.

3. Thompson AJ, Lummis SC. The 5-HT₃ receptor as a therapeutic target. Expert Opin Ther Targets. 2007; 11:527–540. PMID: 17373882.

4. Walstab J, Rappold G, Niesler B. 5-HT(3) receptors: role in disease and target of drugs. Pharmacol Ther. 2010; 128:146–169. PMID: 20621123.

5. Barnes NM, Hales TG, Lummis SC, Peters JA. The 5-HT₃ receptor--the relationship between structure and function. Neuropharmacology. 2009; 56:273–284. PMID: 18761359.

6. Thompson AJ. Recent developments in 5-HT₃ receptor pharmacology. Trends Pharmacol Sci. 2013; 34:100–109. PMID: 23380247.

7. Walstab J, Rappold G, Niesler B. 5-HT(3) receptors: role in disease and target of drugs. Pharmacol Ther. 2010; 128:146–169. PMID: 20621123.

8. Jones BJ, Blackburn TP. The medical benefit of 5-HT research. Pharmacol Biochem Behav. 2002; 71:555–568. PMID: 11888547.

9. Harmer CJ, Reid CB, Ray MK, Goodwin GM, Cowen PJ. 5HT(3) antagonism abolishes the emotion potentiated startle effect in humans. Psychopharmacology (Berl). 2006; 186:18–24. PMID: 16572265.

10. Brunello N, Masotto C, Steardo L, Markstein R, Racagni G. New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology. 1995; 13:177–213. PMID: 8602893.

11. Wada Y, Shiraishi J, Nakamura M, Koshino Y. Effects of the 5-HT₃ receptor agonist 1-(m-chlorophenyl)-biguanide in the rat kindling model of epilepsy. Brain Res. 1997; 759:313–316. PMID: 9221955.

12. Nichols RA, Mollard P. Direct observation of serotonin 5-HT₃ receptor-induced increases in calcium levels in individual brain nerve terminals. J Neurochem. 1996; 67:581–592. PMID: 8764583.

13. Michel K, Zeller F, Langer R, Nekarda H, Kruger D, Dover TJ, Brady CA, Barnes NM, Schemann M. Serotonin excites neurons in the human submucous plexus via 5-HT₃ receptors. Gastroenterology. 2005; 128:1317–1326. PMID: 15887114.

14. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res. 2007; 73:1–52. PMID: 17158031.

15. Rho JM, Sankar R. The pharmacologic basis of antiepileptic drug action. Epilepsia. 1999; 40:1471–1483. PMID: 10565572.

16. Vallés AS, Garbus I, Barrantes FJ. Lamotrigine is an open-channel blocker of the nicotinic acetylcholine receptor. Neuroreport. 2007; 18:45–50. PMID: 17259859.

17. Zheng C, Yang K, Liu Q, Wang MY, Shen J, Vallés AS, Lukas RJ, Barrantes FJ, Wu J. The anticonvulsive drug lamotrigine blocks neuronal {alpha}4{beta}2 nicotinic acetylcholine receptors. J Pharmacol Exp Ther. 2010; 335:401–408. PMID: 20688974.

18. Ahmad S, Fowler LJ, Whitton PS. Lamotrigine, carbamazepine and phenytoin differentially alter extracellular levels of 5-hydroxytryptamine, dopamine and amino acids. Epilepsy Res. 2005; 63:141–149. PMID: 15777732.

19. Ahmad S, Fowler LJ, Whitton PS. Effects of combined lamotrigine and valproate on basal and stimulated extracellular amino acids and monoamines in the hippocampus of freely moving rats. Naunyn Schmiedebergs Arch Pharmacol. 2005; 371:1–8. PMID: 15660242.

20. Southam E, Kirkby D, Higgins GA, Hagan RM. Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats. Eur J Pharmacol. 1998; 358:19–24. PMID: 9809864.

21. Reid JG, Gitlin MJ, Altshuler LL. Lamotrigine in psychiatric disorders. J Clin Psychiatry. 2013; 74:675–684. PMID: 23945444.

22. Large CH, Webster EL, Goff DC. The potential role of lamotrigine in schizophrenia. Psychopharmacology (Berl). 2005; 181:415–436. PMID: 16001126.

23. Li QZ, Cho HS, Jeun SH, Kim KJ, Choi SJ, Sung KW. Effects of grape seed proanthocyanidin on 5-hydroxytryptamine(3) receptors in NCB-20 neuroblastoma cells. Biol Pharm Bull. 2011; 34:1109–1115. PMID: 21720021.

24. Yang HS, Kim SY, Choi SJ, Kim KJ, Kim ON, Lee SB, Sung KW. Effect of 5-hydroxyindole on ethanol potentiation of 5-hydroxytryptamine (5-HT)₃ receptor-activated ion current in NCB-20 neuroblastoma cells. Neurosci Lett. 2003; 338:72–76. PMID: 12565143.

25. Zhou Q, Verdoorn TA, Lovinger DM. Alcohols potentiate the function of 5-HT₃ receptor-channels on NCB-20 neuroblastoma cells by favouring and stabilizing the open channel state. J Physiol. 1998; 507:335–352. PMID: 9518697.

26. Lovinger DM, Sung KW, Zhou Q. Ethanol and trichloroethanol alter gating of 5-HT₃ receptor-channels in NCB-20 neuroblastoma cells. Neuropharmacology. 2000; 39:561–570. PMID: 10728877.

27. Jones MV, Westbrook GL. Desensitized states prolong GABAA channel responses to brief agonist pulses. Neuron. 1995; 15:181–191. PMID: 7542462.

28. Neijt HC, Plomp JJ, Vijverberg HP. Kinetics of the membrane current mediated by serotonin 5-HT₃ receptors in cultured mouse neuroblastoma cells. J Physiol. 1989; 411:257–269. PMID: 2482354.

29. van Hooft JA, van der Haar E, Vijverberg HP. Allosteric potentiation of the 5-HT₃ receptor-mediated ion current in N1E-115 neuroblastoma cells by 5-hydroxyindole and analogues. Neuropharmacology. 1997; 36:649–653. PMID: 9225290.

30. Gunthorpe MJ, Lummis SC. Diltiazem causes open channel block of recombinant 5-HT₃ receptors. J Physiol. 1999; 519:713–722. PMID: 10457085.

31. Maryadale JO, Patricia EH, Peter HD, Kristin JR. The merck index. 15th ed. Cambridge: The Royal Society of Chemistry;2013. p. 5400.

32. Choi JS, Choi BH, Ahn HS, Kim MJ, Rhie DJ, Yoon SH, Min DS, Jo YH, Kim MS, Sung KW, Hahn SJ. Mechanism of block by fluoxetine of 5-hydroxytryptamine3 (5-HT₃)-mediated currents in NCB-20 neuroblastoma cells. Biochem Pharmacol. 2003; 66:2125–2132. PMID: 14609737.

33. Funahashi M, Mitoh Y, Matsuo R. Activation of presynaptic 5-HT₃ receptors facilitates glutamatergic synaptic inputs to area postrema neurons in rat brain slices. Methods Find Exp Clin Pharmacol. 2004; 26:615–622. PMID: 15605121.

34. Liu W, Thielen RJ, McBride WJ. Effects of repeated daily treatments with a 5-HT₃ receptor antagonist on dopamine neurotransmission and functional activity of 5-HT₃ receptors within the nucleus accumbens of Wistar rats. Pharmacol Biochem Behav. 2006; 84:370–377. PMID: 16828150.

35. Turner TJ, Mokler DJ, Luebke JI. Calcium influx through presynaptic 5-HT₃ receptors facilitates GABA release in the hippocampus: in vitro slice and synaptosome studies. Neuroscience. 2004; 129:703–718. PMID: 15541891.

36. Lee S, Hjerling-Leffler J, Zagha E, Fishell G, Rudy B. The largest group of superficial neocortical GABAergic interneurons expresses ionotropic serotonin receptors. J Neurosci. 2010; 30:16796–16808. PMID: 21159951.

37. Thompson AJ, Sullivan NL, Lummis SC. Characterization of 5-HT₃ receptor mutations identified in schizophrenic patients. J Mol Neurosci. 2006; 30:273–281. PMID: 17401153.

38. Thompson AJ, Lummis SC. 5-HT₃ receptors. Curr Pharm Des. 2006; 12:3615–3630. PMID: 17073663.

39. Xie X, Lancaster B, Peakman T, Garthwaite J. Interaction of the antiepileptic drug lamotrigine with recombinant rat brain type IIA Na⁺ channels and with native Na⁺ channels in rat hippocampal neurones. Pflugers Arch. 1995; 430:437–446. PMID: 7491269.

40. Lee CY, Fu WM, Chen CC, Su MJ, Liou HH. Lamotrigine inhibits postsynaptic AMPA receptor and glutamate release in the dentate gyrus. Epilepsia. 2008; 49:888–897. PMID: 18248444.

41. Mirza NR, Bright JL, Stanhope KJ, Wyatt A, Harrington NR. Lamotrigine has an anxiolytic-like profile in the rat conditioned emotional response test of anxiety: a potential role for sodium channels? Psychopharmacology (Berl). 2005; 180:159–168. PMID: 15682295.

Fig. 1

Concentration-dependent inhibition of lamotrigine on the 5-HT₃ receptor currents.

(A) Sample traces show currents activated by 3 µM 5-hydroxytryptamine (5-HT) application (open bar) and co-application of 3 µM 5-HT with 3, 30, 100 µM of lamotrigine (LTG, closed bar) for 5 sec. (B) Representative traces show currents induced by application of 1 mM dopamine (DA) alone (open bar) and co-application with various concentration of lamotrigine (closed bar) for 5 sec. (C~E) A concentration-dependent block of lamotrigine on the peak amplitude and rise slope of 5-HT₃ receptor currents induced by 3 µM 5-HT (n=8) and 1 mM DA (n=6). Data were normalized to the value of the peak current amplitudes and rise slope induced by 3 µM of 5-HT alone or 1 mM DA alone, which was taken as 1. Each data represents mean±S.E.M.

Fig. 2

Competitive inhibition of lamotrigine on the 5-HT₃ receptor currents.

(A) Representative current traces activated by 1, 3, 10, 30 µM of 5-HT alone (open bar) and co-application of 5-HT with 30 µM of lamotrigine (LTG, closed bar), near IC₅₀ from figure 1C. (B) Concentration-response relationship of the peak amplitude of 5-HT₃ receptor currents induced by 0.1, 0.3, 1, 3, 10, 30 µM of 5-HT in the absence (○, n=9) or presence of 30 µM of lamotrigine (●, n=9). Co-application of 30 µM of lamotrigine shifted the EC₅₀ to the right (p<0.05, unpaired t-test) however, the maximum of peak currents, reached at 30 µM of 5-HT, were not significantly different (104.1±1.9% of 10 µM of 5-HT currents for 30 µM 5-HT alone, and 96.1±4.0% for 5-HT with 30 µM LTG; p=0.0843, unpaired t-test). Data were normalized to the value of the peak current amplitudes induced by 10 µM of 5-HT alone, which was taken as 1. Each data represents mean±S.E.M.

Fig. 3

Effects of lamotrigine on the closed state of the 5-HT₃ receptor.

(A) Sample traces show currents evoked by 3 µM 5-HT alone (first), lamotrigine (LTG) co-application without (second) and with (third) 1 min pretreatment of lamotrigine, and 5-HT alone after wash out of lamotrigine for 1 min (fourth). (B) Bar graphs show the averaged peak amplitudes normalized to 3 µM 5-HT alone. There were no significant differences between lamotrigine co-application with and without lamotrigine 1 min pretreatment (n=8, p=0.8586, paired t-test). Data were normalized to the value of the peak current amplitudes induced by 3 µM of 5-HT alone, which was taken as 100%. Each data represents mean±S.E.M.

Fig. 4

Open channel blockade of lamotrigine on 5-HT₃ receptor.

(A) Sample traces show the 5-HT (open bar, 10 µM) and 5-HI (gray bar, 1 mM)-evoked currents and the effects of subsequent treatment of lamotrigine (LTG) on these current (closed bar). The residual currents (time indicated by ▲) after the application of lamotrigine were analyzed for the evaluation of inhibitory effects. (B) Concentration–response relationship of the lamotrigine (1, 3, 10, 30, 100 and 300 µM) on 5-HT₃ receptor currents evoked by the co-application of 5-HT (10 µM) and 1 mM of 5-HI (n=9). Data were normalized to the value of the residual currents measured at the indicated timing in the 5-HT₃ receptor currents induced by 10 µM of 5-HT and 1 mM of 5-HI, which was taken as 1. Each data represents mean±S.E.M.

Fig. 5

Effects of lamotrigine on 5-HT₃ receptor deactivation and desensitization.

(A) Representative traces show currents evoked by 5-HT (10 µM, 10 msec, indicated by arrow) in the absence (left) and presence (right) of lamotrigine (LTG, 30 µM, closed bar). (B) The bar graph shows the averaged effect of lamotrigine on the fast (τ_fast) and slow (τ_slow) component of current decays after a brief application of 5-HT to evaluate the effect of lamotrigine on the 5-HT₃ receptor deactivation (n=8, *p<0.05, paired t-test). (C) Superimposed current traces obtained by the long application (10 sec) of 10 µM 5-HT alone (gray trace) and co-application of 5-HT with 30 µM of lamotrigine (black trace). (D) Averaged bar graph shows the effects of lamotrigine on the τ_fast and τ_slow of current decays after long application of 5-HT to elucidate the effect of lamotrigine on the 5-HT₃ receptor desensitization (n=8, ^*p<0.01, paired t-test). Each data represents mean±S.E.M.

Fig. 6

Voltage-independent inhibition of the 5-HT₃ receptor currents by lamotrigine.

(A) Superimposed traces show the 5-HT₃ receptor currents evoked by 5-HT alone (3 µM, open bar, left) and co-application with lamotrigine (LTG, 30 µM, closed bar, right) at various holding potentials (from −50 mV to +30 mV, 20 mV interval). (B) Averaged data show the I~V relationship in the absence (○) and the presence of lamotrigine (●) (n=7). Data were normalized to the value of the peak amplitudes induced by 5-HT (3 µM, −50 mV) alone, which was set as a −1. (C) Averaged data show a fractional block of lamotrigine (I_5-HT+LTG/I_5-HT) as a function of holding potential. Each data represents mean±S.E.M.

TOOLS

Similar articles